Paul Lizzul
2023
In 2023, Paul Lizzul earned a total compensation of $2.4M as Chief Medical Officer at ANAPTYSBIO, a 36% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,792 |
|---|---|
| Option Awards | $1,131,250 |
| Salary | $509,479 |
| Stock Awards | $570,993 |
| Other | $25,603 |
| Total | $2,441,117 |
Lizzul received $1.1M in option awards, accounting for 46% of the total pay in 2023.
Lizzul also received $203.8K in non-equity incentive plan, $509.5K in salary, $571K in stock awards and $25.6K in other compensation.
Rankings
In 2023, Paul Lizzul's compensation ranked 406th out of 2,978 executives tracked by ExecPay. In other words, Lizzul earned more than 86.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 406 out of 2,978 | 86th |
Division Manufacturing | 230 out of 1,637 | 86th |
Major group Chemicals And Allied Products | 161 out of 906 | 82nd |
Industry group Drugs | 158 out of 869 | 82nd |
Industry Pharmaceutical Preparations | 98 out of 627 | 84th |
Source: SEC filing on April 24, 2024.
Lizzul's colleagues
We found two more compensation records of executives who worked with Paul Lizzul at ANAPTYSBIO in 2023.